naion glp-1 news Popular Type 2 Diabetes Drug Associated with Increased Risk of David Rosenband Named to the

Abbreviations ASCVD: Atherosclerotic CVD CKD: Chronic kidney disease CVOT: Cardiovascular outcome trial DPP-4i: Dipeptidyl peptidase-4 inhibitors EXSCEL: Exenatide Study of Cardiovascular Event Lowering FREEDOM CVO: FREEDOM Cardiovascular Outcomes GIP: Glucose-dependent insulinotropic polypeptide GLP-1: Glucagon-like peptide-1 GLP-1R: Glucagon-like peptide-1 receptor GLP-1RA: Glucagon-like peptide-1 receptor agonist HF: Heart failure LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results MACE: Major adverse cardiovascular event PIONEER: Peptide Innovation for Early Diabetes Treatment 3P-MACE: Three-point major adverse cardiovascular event REWIND: Researching Cardiovascular Events With a Weekly Incretin in Diabetes SGLT2i: Sodiumglucose cotransporter 2 inhibitors SUSTAIN-6: Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes References The Emerging Risk Factors Collaboration (2015) Association of cardiometabolic multimorbidity with mortality

It addresses a completely different set of concerns than levocarnitine

But there's a catch a lot of prescribing doctors don't spend much time on

Mashayekhi M, et al